Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
<0.01Last Year’s EPS
-0.27Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -42.03%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects significant progress with SER-155 and financial improvements, balanced by uncertainties in clinical development timelines and leadership transitions.Company Guidance
During the Q4 2024 earnings call for Seres Therapeutics, substantial guidance was provided about the company's progress and future plans. The company reported a 77% relative risk reduction in bloodstream infections (BSIs) with its lead program, SER-155, in a Phase 1b study. The FDA granted SER-155 a breakthrough therapy designation, and Seres is now preparing for a Phase 2 study, with potential interim results expected within 12 months after initiation. The study's primary efficacy endpoint will be the reduction in BSIs at Day 30 post-HSCT. The company anticipates obtaining full top-line data approximately nine months after interim results. Financially, Seres reported a net loss of $15.7 million for Q4 2024, with cash and equivalents totaling $30.8 million at year-end, and expects to fund operations into Q1 2026, supported by payments received from the VOWST transaction with Nestle.SER-155 Progress and Breakthrough Therapy Designation
Seres advanced their lead program SER-155, aimed at preventing life-threatening bloodstream infections, with a 77% relative risk reduction observed in clinical trials. The FDA granted breakthrough therapy designation for SER-155.
Positive Biomarker and Clinical Data
Exploratory biomarker results support the efficacy of SER-155, indicating a significant reduction in bloodstream infections and positive impacts on systemic immune and inflammatory responses.
Financial Improvements
Net loss from continuing operations decreased from $190.1 million in 2023 to $125.8 million in 2024. The company is now debt-free and expects to fund operations into Q1 2026.
Robust Market Opportunity for SER-155
Market research with healthcare professionals and payers indicates strong interest in SER-155 for preventing bloodstream infections, with significant commercial potential in the allo-HSCT market.
---
MCRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MCRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $0.69 | $0.64 | -7.25% |
| Nov 13, 2024 | $0.66 | $0.59 | -10.61% |
| Aug 13, 2024 | $0.89 | $0.83 | -6.74% |
| May 08, 2024 | $1.11 | $0.75 | -32.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Seres Therapeutics (MCRB) report earnings?
Seres Therapeutics (MCRB) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Seres Therapeutics (MCRB) earnings time?
Seres Therapeutics (MCRB) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCRB EPS forecast?
MCRB EPS forecast for the fiscal quarter 2025 (Q1) is <0.01.
---